Your Personalized Path to
Sustainable Weight Loss

Take a journey that’s tailored to you. At Brello, we use a unique, comprehensive process that puts your biology front and center, leading to lasting weight loss results.

Tirzepatide
Weight Loss Package

$468
$275
SAVE $193
FIRST MONTH with promo code Includes
Tirzepatide
GastroGuard
Get Started

Semaglutide
Weight Loss Package

Semaglutide Product Image
$368
$200
SAVE $168
FIRST MONTH with promo code Includes
Semaglutide
GastroGuard
Get Started

START YOUR Journey with Brello

We’re ready when you are. Start your personalized, biology-driven weight loss journey with Brello today. It’s time to invest in your health, embrace your transformation, and enjoy sustainable weight loss with a plan designed just for you.

Here’s how it works:

Step 1: Complete an Online Form

Fill out our medical intake form so our medical professionals can get to know you and your goals.

Step 2: Assessment Review

Our medical professionals will review your responses to see if you qualify for treatment.

Step 3: Receive Your Prescriptions

If you qualify for treatment, we’ll arrange for convenient monthly shipments of your medications.

START YOUR METABOLIC RESET WITH BRELLO

Uncover a weight loss strategy that addresses the core of the challenge – your unique biology. With Brello, we turn your biological blueprint into your biggest ally in the quest for sustainable weight loss.

We accept the following forms of payment
LegitScript approved

References:

  1. https://www.fda.gov/news-events/press-announcements/fda-approves-new-medication-chronic-weight-management
  2. Azuri J, Hammerman A, Aboalhasan E, Sluckis B, Arbel R. Tirzepatide versus semaglutide for weight loss in patients with type 2 diabetes mellitus: A value for money analysis. Diabetes Obes Metab. 2023; 25(4): 961-964. doi:10.1111/dom.14940
  3. Aronne LJ, Sattar N, Horn DB, et al. Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial. JAMA. 2024;331(1):38–48. doi:10.1001/jama.2023.24945